NAMS תחזית צמיחת רווחים לשנה הבאה newamsterdampharma.com

The earnings per share forecast for next year demonstrates that the current parameter is -28.00. NewAmsterdam Pharma (NAMS) business development relies on the success of clinical trials and regulatory approvals. Stable free cash flow is ensured by patent protection within the metabolic pathology niche. Meanwhile, the active R&D phase for the CETP inhibitor guarantees the company a strong position in the cardiology sector.
NAMS (NewAmsterdam Pharma Company): פילוחים אנליטיים ודוחות לפי אינדיקטורים

During fundamental asset screening, this indicator serves as a leading signal of market expectations for earnings per share. By analyzing the expected EPS growth for the coming year, an investor can observe a smoothed vector of consensus forecasts, which for NewAmsterdam Pharma (NAMS) directly reflects the potential commercial success of obicetrapib as an affordable alternative to injectable methods for treating hypercholesterolemia.